Our results suggest that STINGR284S mRNA-LNP can overcome the toxicity and limitations of conventional STING agonists and therefore could be exploited as a new therapeutic approach for treating an array of STING-deficient cancers that are refractory to current therapies. Here, STING1 is linked to cancer.